Print version | PDF version | Send article | RSS feed

Lexicon Genetics changes name and refocuses business

Refocusing Business to Achieve Goal of Advancing Ten Drug Candidates into Human Clinical Trials by 2010

31 Jan 2007 - Lexicon Genetics Incorporated announced that it is changing its name to Lexicon Pharmaceuticals, Inc. to reflect that it is focusing its operations on drug discovery and development activities related to its 10to10 Program. The 10to10 Program is an ongoing company initiative with the goal of advancing ten drug candidates into human clinical trials by 2010. Lexicon's planned name change will be submitted for shareholder approval at its upcoming annual shareholder meeting.
 
Lexicon expects the 10to10 clinical development programs to result from its internal drug discovery efforts as well as from efforts with collaborators. Lexicon has two proprietary compounds in human clinical trials and anticipates filing investigational new drug applications for two additional compounds in 2007.